Opinion: Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls

When Eli Lilly announced in 2017 that it would stop producing quinidine, it was the only medication approved for severe malaria treatment in the U.S.

As quinidine supplies dwindled, the Centers for Disease Control and Prevention made available artesunate, a better drug that is the international gold standard for treating severe malaria, free of charge via request. But that process posed problems.

Read the rest…

Opinion: Unaffordable treatment for severe malaria highlights U.S. drug market pitfalls

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top